Carla Rothlin

Carla Rothlin, PhD, is the Dorys McConnell Duberg Professor of Immunobiology and Professor of Pharmacology at the Yale School of Medicine. She co-leads the Cancer Immunology Program at the Yale Cancer Center and holds secondary appointments in Pharmacology. Her research focuses on immune homeostasis, TAM receptor tyrosine kinases, and inflammation. Key affiliations include the Immunobiology Department, the Interdepartmental Neuroscience Program, and the Yale Fibrosis Program.

Education:

• PhD in Immunobiology, University of Buenos Aires (2002)

Research Interests: Dr. Rothlin’s work explores how immune cells respond to apoptotic cells and regulate inflammation, with a focus on TAM receptors (MERTK, AXL, TYRO3) in cancer immunology, tissue repair, and neurodegenerative diseases. Her lab investigates mechanisms linking cholesterol metabolism, dendritic cell function, and anti-tumor immunity. Recent studies address IL-4/IL-13 signaling in macrophage-driven tissue remodeling and the roles of TREM2 in glioblastoma microenvironments.

Publications: Her 2024-2025 work highlights breakthroughs in cholesterol-mediated dendritic cell maturation, MERTK knockout models, and the intersection of myelin phagocytosis with neuroinflammation. Her articles frequently bridge immunology with oncology, neuroscience, and pharmacology.

Awards:

• Howard Hughes Medical Institute (HHMI) Faculty Scholar (2016)
• American Asthma Foundation Early Excellence Award (2011)
• Lupus Research Institute Novel Research Grant (2011)

Grants & Advising: As a leader in cancer immunology, she has secured major grants and advised on peer review reforms. Her lab (Rothlin Ghosh Lab) collaborates extensively, with frequent co-publications in Nature Immunology, Science, and Immunity.

Labs/Teams: Director of the Rothlin Ghosh Lab, part of the Yale Cancer Center and Yale Stem Cell Center.